Organon outsources global support organization to Atos Origin
N.V. Organon, a global pharmaceutical company, and Atos Origin, an international IT services company, signed a contract for the outsourcing of the global infrastructure support services. Atos Origin will introduce and maintain uniform high-standard support services to the business operations of Organon worldwide.

Paris, Oss, the Netherlands, 10 May, 2007 -

With this agreement Organon will benefit from a professionally managed 7*24 hours support organization while at the same time lowering their operational costs. Vincent van Geerestein, senior vice president Global ICT at Organon says: "Maintaining the flexibility, trust and responsiveness to the business demand of Organon forms the basis to the business relationship between Organon and Atos Origin".

Ed van Nigtevecht, executive director Information Services at Organon says: "The objective of Organon with this global outsourcing contract is to establish high-standard levels of uniform support services in our business operations, while maintaining the flexibility to exclude or expand functionality in the future. We have worked before with Atos Origin on various projects and look forward to continue the cooperation on a service level basis".

Samir El Awadi, vice president Healthcare and Pharma at Atos Origin concludes: "This outsourcing initiative is yet another significant step in Atos Origin’s partnership with Organon and clearly confirms a new phase in the business relationship with the new mother company Schering-Plough. Atos Origin has a solid track record in the healthcare and pharmaceutical industry and builds on its global managed operations experience. In this project we take a pragmatic approach to package-enabled process change in a regulated environment.

About Organon

Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.

About Atos Origin

Atos Origin is an international information technology services company. Its business is turning client vision into results through the application of consulting, systems integration and managed operations. The company's annual revenues are EUR 5.4 billion and it employs 50,000 people in 40 countries. Atos Origin is the Worldwide Information Technology Partner for the Olympic Games and has a client base of international blue-chip companies across all sectors. Atos Origin is quoted on the Paris Eurolist Market and trades as Atos Origin, Atos Euronext Market Solutions, Atos Worldline and Atos Consulting.

For more information:

Ingrid Clauwaert

+ 31 30 299 5007

José de Vries

+ 33 1 55 91 24 53

Safe Harbor Statement Organon *

This press release may contain statements which address such key issues as Akzo Nobel’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company’s corporate website The 2006 Annual Report on Form 20-F will be available in the second quarter of 2007.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.